Since 1998, AURIGA PARTNERS, an independent Venture Capital firm, has been managing several early stage funds specializing in Information
Business Model:
Revenue: $0
Employees: 0-0
Address: 14, Bd de la Madeleine
City: Paris
State: île-de-france
Zip: 75008
Country: FR
Since 1998, AURIGA PARTNERS, an independent Venture Capital firm, has been managing several early stage funds specializing in Information Technology and Life Sciences.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
6/2017 | VitaDX | Seed Round | 1.8M |
6/2014 | Fab&s;entech | Series A | 6.8M |
4/2014 | eXo Platform | Venture Round | 1.2M |
3/2010 | eXo Platform | Series A | 6M |
6/2014 | Wallix | Venture Round | - |
11/2011 | Wallix | Series A | 6.9M |
5/2014 | Convertigo | Venture Round | 1.5M |
9/2009 | Convertigo | Series A | 4.3M |
1/2003 | Drug Abuse Sciences | Series B | 1.9M |
3/2011 | Availpro | Series B | 3.6M |
2/2013 | Codenvy | Series A | 9M |
7/2014 | Amoeba | Series A | 889.1k |
1/2006 | Neolane | Series B | 6.6M |
8/1999 | NEMOPTIC | Series A | 2.5M |
9/2010 | Eve.com | Venture Round | 454.6k |
3/2007 | Alchimedics | Series A | 3.3M |
10/2013 | Genocea Biosciences | Series D | 16.1M |
1/2016 | Pylote | Venture Round | 2.2M |
5/2006 | NEMOPTIC | Series D | 0 |
2/2008 | TxCell | Series B | 15.6M |
1/2000 | Santen Pharmaceutical | Post-IPO Equity | 3.8M |
9/2009 | Bonitasoft | Series A | 3M |
3/2003 | NEMOPTIC | Series C | 12M |
3/2006 | SuperSonic Imagine | Series A | 11.9M |
5/2004 | Pharma Omnium | Series B | 2.4M |
6/2009 | Implanet | Series B | 12.6M |
2/2009 | Genocea Biosciences | Series A | 23M |
6/2004 | Emulation and Verification Engineering | Venture Round | 7.2M |
12/2009 | Evolva | Post-IPO Equity | 27.5M |
12/2006 | Eve.com | Series B | 6.7M |
6/2004 | Eve.com | Series A | 7.2M |
4/2007 | Nautilus Biotech | Venture Round | 0 |
4/2011 | Isocell | Series A | 4.3M |
11/2014 | Theranexus | Seed Round | 4.5M |
9/2010 | Nexthink | Series A | 4.9M |
1/2015 | CoLucid Pharmaceuticals | Series C | 0 |
12/2010 | Median Technologies | Series E | 13.1M |
10/2009 | Evolva | Series B | 27.8M |
3/2004 | Innovative Silicon | Series A | 6M |
12/2006 | erytech | Venture Round | 15.8M |
1/2002 | Innate Pharma | Series B | 17.8M |
3/2000 | Innate Pharma | Series A | 4.4M |
6/2016 | One More Company | Seed Round | - |
10/2006 | Domain Therapeutics | Series C | 10.4M |
10/2008 | SuperSonic Imagine | Series B | 25.7M |
9/2009 | Santen Pharmaceutical | Post-IPO Equity | 22M |
3/2005 | Nautilus Biotech | Venture Round | 0 |
4/2009 | Population Genetics Technologies | Series A | 3.2M |
10/2011 | Population Genetics Technologies | Series B | 5.7M |
3/2014 | Stantum | Venture Round | 626.9k |
7/2012 | Domain Therapeutics | Venture Round | 2.5M |
11/2012 | TxCell | Series C | 16.1M |
7/2005 | Bag Tech | Series B | 9.9M |
7/2003 | Bag Tech | Series A | 2.9M |
7/2008 | Bag Tech | Series D | 2.9M |
5/2002 | Neolane | Series A | 1.8M |
6/2017 | Vectalys | Venture Round | 0 |
9/2005 | SpinX | Series B | 12.5M |
6/2004 | OXAND | Venture Round | 1.9M |
3/2000 | Aquarelle | Series B | 25.5M |
9/2011 | Bonitasoft | Series B | 11M |
6/2013 | Miliboo | Series B | 5.2M |
6/2012 | Wallix | Venture Round | - |
1/2007 | Neolane | Series B | 6.5M |
11/2011 | CYTOO | Series C | 10M |
9/2011 | Implanet | Series D | 7.6M |
1/2010 | IDbyME | Series A | 2.9M |
7/2010 | erytech | Series B | 6.2M |
12/2000 | Entomed | Series B | 17.9M |
6/2005 | Theradiag | Series C | 6.1M |
4/2012 | Eptica | Venture Round | 9.1M |
6/2014 | Nexthink | Corporate Round | 20.8M |
10/2009 | Pharma Omnium | Venture Round | 109k |
8/2007 | Median Technologies | Series D | 4.6M |
7/2011 | erytech | Series C | 5.8M |
2/2002 | Domain Therapeutics | Series A | 2.6M |
11/2013 | Implanet | Series E | 25.3M |
4/2014 | TxCell | Venture Round | 21.4M |
11/2004 | Median Technologies | Series B | 5.1M |
12/2014 | Pherecydes Pharma | Series A | 2.4M |
10/2006 | Bag Tech | Series C | 6.1M |
5/2013 | aveni | Series E | 4.5M |
4/2006 | Santen Pharmaceutical | Post-IPO Equity | 31.5M |
2/2017 | TxCell | Post-IPO Equity | 11.6M |
10/2009 | CYTOO | Series B | 4.7M |
5/2022 | Vade Secure | Venture Round | 0 |
5/2018 | Flash Therapeutics | Private Equity Round | 3.9M |
4/2013 | SuperSonic Imagine | Private Equity Round | 0 |
11/2010 | SuperSonic Imagine | Series C | 0 |
1/2007 | Nexthink | Corporate Round | 3.3M |
10/1999 | Drug Abuse Sciences | Venture Round | 22.4M |
10/2007 | Ekinops | Series B | 20M |
3/2007 | Streamcore System | Series B | 0 |
6/2010 | Ekinops | Series D | 0 |
5/2009 | Ekinops | Series C | 4M |
4/2007 | Theraptosis | Series B | 11.2M |
1/2005 | Biolipox | Series C | 41M |
2/1999 | Aquarelle | Series A | 4.1M |
9/2004 | Santen Pharmaceutical | Post-IPO Equity | 11.2M |
10/2006 | Open-Plug | Series B | 15M |
4/2003 | Ekinops | Series A | 7.6M |
5/2007 | Implanet | Series A | 17.7M |
5/2013 | Bonitasoft | Series C | 13M |
5/2004 | Domain Therapeutics | Series B | 19.1M |
7/2015 | aveni | Series A | 13.5M |
10/2017 | aveni | Series B | 10.5M |
9/2005 | NemeriX | Series B | 0 |
9/2007 | NemeriX | Series C | 0 |
1/2018 | Pherecydes Pharma | Series B | 10.7M |
3/2015 | Pherecydes Pharma | Venture Round | 2.7M |
11/2013 | Nosopharm | Venture Round | 1.2M |
2/2011 | CellNovo | Series B | 48.3M |
11/2003 | Santen Pharmaceutical | Post-IPO Equity | 5.8M |
12/2007 | NGI | Series A | 11.8M |
12/2001 | Hybrigenics | Series B | 11.6M |
10/2008 | Pharma Omnium | Series E | 4.2M |
2/2007 | Pharma Omnium | Series D | 3M |
11/2005 | Pharma Omnium | Series C | 4.8M |
10/2001 | Gamida Cell | Series B | 9.7M |
7/2013 | Firalis | Series B | 0 |
1/2012 | Amplitude | Series B | 39.1M |
1/2003 | Biolipox | Series B | 21M |
5/2000 | Gamida Cell | Series A | 6.4M |
9/2004 | Innate Pharma | Series C | 0 |
1/2003 | Orexo | Series B | 22.4M |
1/2000 | Theradiag | Series A | 4.6M |
4/2018 | EnobraQ | Seed Round | 3.6M |
3/2009 | Stantum | Series B | 16.4M |
1/2012 | Neolane | Venture Round | 27M |
12/2009 | Genocea Biosciences | Series B | 25.7M |
4/2010 | Implanet | Series C | 10.8M |
6/2005 | Innovative Silicon | Series B | 16M |
1/2012 | IDbyME | Series B | 0 |
3/2001 | Drug Abuse Sciences | Series A | 46.5M |
8/2005 | aveni | Series B | 14.6M |
12/2002 | Catalyst Bioscience | Venture Round | 46M |
8/2014 | Median Technologies | Post-IPO Equity | 26.4M |
4/2016 | Nexthink | Series B | 48.9M |
6/2023 | Exeliom | Series A | 8.7M |
3/2017 | Nosopharm | Venture Round | 0 |
11/2007 | Innovative Silicon | Series C | 25M |
3/2013 | Population Genetics Technologies | Series G | 469k |
9/2012 | Population Genetics Technologies | Series F | 1.6M |
12/2010 | Population Genetics Technologies | Venture Round | 2.5M |
2/2008 | Population Genetics Technologies | Series A | 7.4M |
7/2018 | Exeliom | Series A | 8.2M |
4/2007 | aveni | Series C | 0 |
6/2022 | Patrowl | Seed Round | 2.1M |
6/2000 | Hybrigenics | Series A | 8.5M |
4/2013 | erytech | Series D | 19.3M |
5/2012 | Gamida Cell | Series E | 0 |
7/2006 | Median Technologies | Series C | 12.8M |
8/2005 | Gamida Cell | Series C | 3.7M |
6/2003 | Milagen | Series B | 3.6M |
12/2000 | Milagen | Series A | 839.3k |
10/2003 | TiGenix | Venture Round | 14M |
1/2011 | Miliboo | Series A | 3.4M |
5/2003 | Theradiag | Series B | 10.4M |
8/1999 | ConjuChem | Series B | 8.5M |
10/2014 | aveni | Series F | 2.8M |
2/2000 | Spine Next | Series A | 11.7M |
5/2022 | Vade Secure | Venture Round | 0 |
7/2018 | Exeliom | Series A | 0 |
5/2018 | Flash Therapeutics | Private Equity Round | 0 |
4/2018 | EnobraQ | Seed Round | 0 |
1/2018 | Pherecydes Pharma | Series B | 0 |
10/2017 | aveni | Series B | 0 |
6/2017 | Vectalys | Venture Round | 0 |
6/2017 | VitaDX | Seed Round | 0 |
3/2017 | Nosopharm | Venture Round | 0 |
2/2017 | TxCell | Post-IPO Equity | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|